StockDrifts LogoStockDrifts

Genexine 095700

Company
제넥신Genexine
Insiders
0
Buys
0
Total Value
—
Avg Return
—
Last Filing
2024-10-17

Genexine (095700) has 0 disclosed insider purchases and 0 disclosed disposals on record, filed by 0 distinct insiders. The earliest filing StockDrifts holds for Genexine is dated 2024-10-17; the most recent is 2024-10-17.

Price & insider activity (12 months)

Recent insider trades

DateTypeSourceInsiderPositionSharesPrice at filingReturnValue
2024-10-17BUY합병
용예령
Yongyeryeong
moving156.6K₩9,350-50.8%₩1.5B ($1.0M)
2024-10-17BUY합병
최재현
Jaehyun Choi
vice president1.7M₩9,350-50.8%₩15.8B ($11.0M)
2024-10-17BUY합병
이승현
Seunghyun Lee
Managing Director563.7K₩9,350-50.8%₩5.3B ($3.7M)

Frequently asked questions

Who has been buying Genexine stock?
0 distinct insiders have filed 0 disclosed insider purchases in Genexine (095700), most recently on 2024-10-17. Each filer, their role, the number of shares and the price at filing are listed in the table on this page.
How many insider filings does Genexine have?
Genexine has 0 buy-side and 0 sell-side disclosures on record, spanning 2024-10-17 to 2024-10-17.
Do insider buys in Korean stocks predict returns?
Not uniformly. StockDrifts analysed 170,720 share-count changes across 56,930 Korean regulatory filings using cross-sectional alpha at fixed forward horizons, and found returns concentrated in particular signal tiers rather than in insider buying generally.

More on this data

Every trade listed above comes from an official regulatory disclosure. For how StockDrifts scores these disclosures, see the Korea insider signal tier research, or browse every Korean stock we track.